Standalone & Consolidated Financial Results, Limited Review Report for September 30, 2016
Zydus Wellness Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Consolidated Financial Results for the period ended September 30, 20163. Standalone Limited Review for the period ended September 30, 20164. Consolidated Limited Review for the period ended September 30, 2016 Intimation of Schedule of Analyst / Institutional Investor Meetings
Zydus Wellness Ltd has informed BSE about Schedule of Analyst / Institutional Investor Meet Zydus Wellness independent director B M Hegde resigns
Zydus Group firm Zydus Wellness today said its independent director B M Hegde has resigned due to personal reasons. Dr B M Hegde, an independent director of the company, has resigned with immediate... Resignation of Independent Director
Zydus Wellness Ltd has informed BSE that Dr. B. M. Hegde, an Independent Director of the Company has resigned with immediate effect due to personal reasons. Pursuant to his resignation, he also ceased to be the member of the Committees of the Board of Directors, in which he was a member.The Directors, vide Circular Resolution, have accepted the resignation. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Board Meeting Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on October 25, 2016, to consider apart from other agenda items to approve the unaudited financial results for the quarter / half year ended on September 30, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will... Zydus to market immunosuppressant drug of Switzerland's Neovii in India
The company has inked in-licensing pact with Swiss firm for the launches Grafalon, an immunosuppressant extensively used in solid organ transplants and stem cell transplant
Zydus partners Takeda to develop, market vaccine for chikungunya
The broad-based agreement between Zydus and Takeda includes early-stage development to the final commercialisation of the vaccine for chikungunya Zydus acquires derma brand Melgain from Issar Pharma
The brand will be marketed by Liva Healthcare, the group's division catering to dermatological segment